Skip to content

Clinical Study on Efficacy of Zhu's Tiaojing Cuyun Recipe in the Treatment of Infertility in Polycystic Ovary Syndrome (Kidney Deficiency Type)

Clinical Study on Efficacy of Zhu's Tiaojing Cuyun Recipe in the Treatment of Infertility in Polycystic Ovary Syndrome (Kidney Deficiency Type)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000880
Enrollment
Unknown
Registered
2025-04-28
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome

Interventions

Treatment group:Tiaojing Cuyun Recipe
Control group:Letrozole Tablets

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of TCM
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1) Women aged 20 to under 40 years old who have a desire for fertility; 2) Patients who meet the Western medical diagnostic criteria for infertility caused by polycystic ovary syndrome (PCOS) and the traditional Chinese medicine diagnostic criteria for the kidney deficiency syndrome type; 3) Individuals who voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Individuals with infertility caused by genetic factors; 2) Individuals with infertility due to congenital gonadal dysgenesis or malformations; 3) Individuals with infertility caused by tubal factors immune factors endometriosis adenomyosis uterine fibroids ovarian tumors or non-physiological cysts; 4) Individuals with severe primary diseases of the cardiovascular liver kidney or hematological systems and those with severe mental illnesses; 5) Individuals who have used hormones or related/antagonistic drugs within the past 3 months making it difficult to assess drug efficacy; 6) Individuals whose partners have abnormal reproductive functions; 7) Patients who are currently participating in other clinical trials; 8) Individuals who are allergic or have a severe allergic constitution to the drugs used in this trial; 9) Pregnant women.

Design outcomes

Primary

MeasureTime frame
Pregnancy (urine pregnancy test positive) rate;

Secondary

MeasureTime frame
Intestinal flora;Metabolism-related index;Menstrual symptom score;TCM syndrome score;Basal serum sex hormone levels;Number of ovulation cycles (rate) number of follicular luteinization (rate) endometrial thickness during ovulation;

Countries

China

Contacts

Public ContactJiangZhuojun

Yueyang Hospital of Integrated Traditional Chinese and Western MedicineShanghai University of TCM

819709252@qq.com13482728180

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026